Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

1-furan-2-yl-3-pyridin-2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP

Authors
Park, Byung ChulThapa, DineshLee, Yoon-SeokKwak, Mi-KyoungLee, Eung-SeokChoi, Han GonYong, Chul SoonKim, Jung-Ae
Issue Date
Jul-2007
Publisher
ELSEVIER SCIENCE BV
Keywords
1-furan-2-yl-3-pyridin-2-yl-propenone; MMP-2; MMP-9; MT1-MMP; TIMP
Citation
EUROPEAN JOURNAL OF PHARMACOLOGY, v.567, no.3, pp.193 - 197
Indexed
SCIE
SCOPUS
Journal Title
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume
567
Number
3
Start Page
193
End Page
197
URI
https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/43534
DOI
10.1016/j.ejphar.2007.04.014
ISSN
0014-2999
Abstract
Matrix rnetalloproteinases (MMPs) play important roles in solid tumor invasion and migration. In this study, we showed that 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3) dose-dependently inhibited HT1080 cell invasion and migration, and decreased NIMP-2 and MMP-9 activities. Furtherniore. FPP-3 reduced MMP-2 expression at protein and inRNA levels, and suppressed 12-0-tetradecanoylphorbol-13-acetate (TPA)enhanced expression of MTl-MMP without changing tissue inhibitors of rnetalloproteinase (TIMP)-2 level. FPP-3 also suppressed TPA-induced increases in MMP-9 protein and rnRNA levels, but did not alter TIMP-1 level. Our results suggest that FFP-3 may be a valuable anti-invasive drug candidate for cancer therapy by suppressing MMP-2, MMP-9, and MT1-MMP. (C) 2007 Elsevier B.V. All rights reserved.
Files in This Item
Go to Link
Appears in
Collections
COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Choi, Han Gon photo

Choi, Han Gon
COLLEGE OF PHARMACY (DEPARTMENT OF PHARMACY)
Read more

Altmetrics

Total Views & Downloads

BROWSE